Related Experiment Video

Updated: Aug 14, 2026

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections
09:11

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections

Published on: August 11, 2012

Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study

I Kuzman1, K Oresković, S Schönwald

  • 1University Hospital of Infectious Diseases Dr. Fran Mihaljević, Zagreb.

International Journal of Clinical Pharmacology Research
|January 1, 1996
PubMed

Insights

Azithromycin and doxycycline are equally effective and well-tolerated treatments for Chlamydia pneumoniae pneumonia. Both antibiotics demonstrated complete cure rates and similar fever resolution times in this comparative study.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Pneumonia caused by Chlamydia species requires effective antimicrobial therapy.
  • Azithromycin and doxycycline are common antibiotics used for respiratory infections.
  • Comparative data on their efficacy and safety in treating Chlamydia-induced pneumonia is valuable.

Purpose of the Study:

  • To compare the efficacy and safety of azithromycin versus doxycycline for treating Chlamydia spp. pneumonia.
  • To evaluate treatment outcomes, including cure rates and fever duration.
  • To assess the tolerability of both antibiotic regimens.

Main Methods:

  • Retrospective study of patients with radiologically confirmed pneumonia and positive chlamydial serology.
  • Analysis of patients treated with azithromycin (3- or 5-day courses) or doxycycline (10-day course).
  • Comparison of treatment groups based on age, sex, illness severity, cure rates, fever duration, and adverse events.

Main Results:

  • All patients in both treatment groups achieved a complete cure.
  • No significant difference in fever duration was observed between azithromycin and doxycycline treatments.
  • Both azithromycin (3- and 5-day courses) and doxycycline were well-tolerated, with minimal adverse effects reported.

Conclusions:

  • Azithromycin is as effective and safe as doxycycline for treating Chlamydia spp. pneumonia.
  • Short-course azithromycin regimens (3 or 5 days) are effective alternatives.
  • Both antibiotics offer favorable safety profiles for this indication.

More Related Videos

Forward Genetic Approaches in Chlamydia trachomatis09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...